Treatment of fibrosing cholestatic hepatitis with lamivudine-Reference-Cited by-同舟云学术

Treatment of fibrosing cholestatic hepatitis with lamivudine

Published:1998-07 Issue:1 Volume:115 Page:177-181
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Chan Tak–Mao,Wu Pui–Chee,Li Fu–Keung,Lai Ching–Lung,Cheng Ignatius K.P.,Lai Kar–Neng

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference24 articles.

1. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection;Fornairon;Transplantation,1996

2. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B–positive and B–negative renal transplant recipients;Rao;Transplantation,1991

3. The impact of renal transplantation on the course of hepatitis B liver disease;Parfrey;Transplantation,1985

4. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis;Davies;Hepatology,1991

5. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis;Lau;Gastroenterology,1992

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrosing cholestatic hepatitis as a variant of the course of hepatotropic viruses’ infection;Epidemiology and Infectious Diseases;2024-06-10

2. Influence of donor and recipient hepatitis B virus infection on long‐term outcomes after kidney transplantation;Clinical Transplantation;2021-10-21

3. Long‐term data on entecavir treatment for treatment‐naive or lamivudine‐resistant chronic hepatitis B infection in kidney transplant recipients;Transplant Infectious Disease;2019-07-18

4. Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service;Nephrology;2019-03

5. Liver Disease Among Renal Transplant Recipients;Kidney Transplantation - Principles and Practice;2019